Skip to main content
Nectar Lifesciences Limited logo

Nectar Lifesciences Limited — Investor Relations & Filings

Ticker · NECLIFE ISIN · INE023H01027 LEI · 335800RY4LGC64KN9C05 BSE.NS Manufacturing
Open in API
Filings indexed 538 across all filing types
Latest filing 2026-03-06 Capital/Financing Update
Country IN India
Listing BSE.NS NECLIFE

About Nectar Lifesciences Limited

https://www.neclife.com/

Nectar Lifesciences Limited is a pharmaceutical organization specializing in the development and manufacturing of Active Pharmaceutical Ingredients (APIs) and finished dosage forms. The company maintains a significant focus on the cephalosporin segment, producing a wide range of oral and sterile products including Cefixime, Cefuroxime Axetil, and Ceftriaxone. Its operations encompass a fully integrated business model supported by large-scale manufacturing facilities that adhere to international regulatory standards such as USFDA and EUGMP. In addition to its core antibiotic portfolio, the company produces menthol and phytochemicals. Nectar Lifesciences serves a global clientele through contract manufacturing and development services, leveraging its research and development capabilities to provide high-quality therapeutic solutions across various international markets.

Recent filings

Filing Released Lang Actions
Acquisition
Capital/Financing Update Classification · 95% confidence The document is a formal notification from Nectar Lifesciences Ltd. addressed to stock exchanges regarding the acquisition of 100% equity share capital of Avensis Exports Private Limited, making it a wholly owned subsidiary. It references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, indicating it is a regulatory disclosure. The document is short (2287 characters) and serves as an announcement of a corporate event (acquisition) rather than a detailed merger filing or full report. It does not contain detailed financial statements or merger proxy materials. Therefore, it fits best under Capital/Financing Update (CAP) as it updates on a financing/capital structure change through acquisition.
2026-03-06 English
General Updates
Board/Management Information Classification · 95% confidence The document is a formal communication from Nectar Lifesciences Ltd. addressed to stock exchanges, reporting the outcome of a board meeting held on March 2, 2026. It discloses the board's decision to approve an inter-corporate loan to a proposed wholly owned subsidiary after acquisition. The document references compliance with SEBI regulations and mentions that detailed disclosures will be provided later. The document is short (2708 characters) and serves as an announcement of decisions made at the board meeting rather than a full report or financial statement. It does not contain financial data or detailed management discussion but rather informs about board decisions and regulatory compliance disclosures. Therefore, it fits best under Board/Management Information (MANG), which covers announcements of changes or decisions by the board of directors or senior management.
2026-03-03 English
Acquisition
Regulatory Filings Classification · 95% confidence The document is a formal communication from Nectar Lifesciences Ltd. addressed to stock exchanges, reporting the outcome of a board meeting held on March 2, 2026. The key points disclosed include the approval to acquire 100% equity of Avensis Exports Private Limited and a change in the Registrar and Share Transfer Agent. The document references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events to stock exchanges. The content is an announcement of decisions made by the board rather than a detailed report or financial statement. It does not contain financial results, audit opinions, or detailed management analysis. The document length is 7,189 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Regulatory Filing (RNS), which is the fallback category for regulatory announcements and disclosures that do not fit other specific categories.
2026-03-02 English
Outcome of Board Meeting
Capital/Financing Update Classification · 95% confidence The document is a formal communication from Nectar Lifesciences Ltd. addressed to stock exchanges, reporting the outcome of a board meeting held on March 2, 2026. The key points disclosed are the approval to acquire 100% equity of Avensis Exports Private Limited and a change in the Registrar and Share Transfer Agent. The document references compliance with SEBI Listing Obligations and Disclosure Requirements Regulations, 2015, specifically Regulation 30, which pertains to disclosure of material events. The content is an announcement of decisions made by the board rather than a detailed report or financial statement. It includes annexures providing details about the acquisition and the RTA change but does not contain financial statements or comprehensive analysis. The document length is 7189 characters, which is relatively short and consistent with an announcement rather than a full report. Therefore, this filing is best classified as a Capital/Financing Update (CAP) because it announces a significant acquisition and a change in company service providers related to share registry, both of which impact the company's capital structure and operations.
2026-03-02 English
Shareholders meeting
Regulatory Filings
2026-03-01 English
Reply to Clarification- Financial results
Regulatory Filings Classification · 95% confidence The document is a letter from Nectar Lifesciences Ltd. addressed to the National Stock Exchange of India, clarifying details about the financial results for the quarter ended September 30, 2025. It references an independent auditor's report on consolidated financial results, which is attached for reference. The letter explains that the subsidiary had no business activity and that standalone and consolidated results are the same. The document is short (1865 characters) and primarily serves as a clarification or explanatory note rather than presenting full financial statements or detailed financial data. It does not contain actual financial results or comprehensive report content but refers to an attached auditor's report. Therefore, this document is best classified as a Regulatory Filing (RNS), which covers miscellaneous regulatory announcements and clarifications that do not fit other categories.
2026-02-10 English

Browse filings by year

17 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.